RP-3 by Replimune for Melanoma: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Melanoma.

Village Farms Q1 Cannabis Sales Fall 10% Sequentially

Village Farms International Reports Financial Results for First Quarter 2023 Canadian Cannabis Business Maintains Number Two Market Share Position Nationally, Including Number Two Position in

May 10, 2023

PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders

PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER™.

May 22, 2024

Researchers create high-performing, eco-friendly sunscreen

In a significant breakthrough for the cosmetics industry, researchers have developed a new type of sunscreen using lignin, a naturally abundant polymer, and titanium dioxide

September 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.